OpenNashPodcasts

The Readout Loud (STAT)

Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout

23 Sep 2021 · 36m · Meg Terrell, Helen Branswell · 21 quoted facts

▶ Play episodeOriginal source ↗

In brief

The episode argues that the U.S. entered the Covid winter of 2021 still unprepared in ways that were foreseeable. Helen Branswell says models suggest the Delta wave could ebb after Thanksgiving, but only if no new variant appears. Scott Gottlieb argues that pandemic planning focused on flu, neglected testing, and left a CDC that lost public trust.

The main tension is between short-term hope and long-term fragility. Models are cautiously optimistic, yet booster rules are messy, global vaccine supply is thin, and public confidence in health agencies has eroded. A lighter thread follows Biogen's Aduhelm, which approval did not turn into patients: only about 100 had been treated, held back by skepticism, logistics and price.

Key insights

  1. Planning for flu left the U.S. exposed

    Gottlieb says tabletop exercises like Crimson Contagion assumed an influenza pandemic, where testing matters less because people are contagious only after symptoms. Covid spread silently, so the missing testing capacity became decisive.

  2. The national stockpile held unusable equipment

    Gottlieb says stockpiled respirators did not work and masks were out of date. He calls the stockpile one metaphor for how thin the preparations were.

  3. Booster rules are loose and honor-based

    The FDA authorized Pfizer boosters for people 65 and older and for many high-risk or high-exposure groups. Branswell notes no one checks eligibility, and the authorization leaves out Moderna and J&J recipients.

  4. Models see Delta fading after Thanksgiving

    A modeler at NIH's Fogarty center told Branswell that the models point to cases falling to roughly 10,000 to 15,000 a day. That outlook depends on no new, more transmissible or immune-evading variant emerging.

  5. Aduhelm's launch stalled on trust, logistics and price

    About 100 people had received it commercially by September 11, 2021, far below Wall Street hopes. Skeptical doctors, the need for monthly infusions, and a $56,000 average annual price all slowed it.

Questions

Why was the U.S. so unprepared for Covid?

Gottlieb says planning assumed the next pandemic would be flu, so exercises and stockpiles ignored things like large-scale diagnostic testing. The CDC also botched its first Covid test and gave guidance that people found arbitrary.

Could I have gotten a Covid booster shot in September 2021 if I wasn't high-risk?

Probably yes in practice. Helen Branswell said eligibility has always been an honor system, and she doubted a pharmacist would ask how you qualify.

Was winter 2021–22 expected to be bad?

Branswell reported that models pointed to the Delta wave subsiding after Thanksgiving. She cautioned that a new variant able to escape immunity or spread faster could change that.

Why wasn't Aduhelm selling well?

Only about 100 people had received it commercially by September 11, 2021. Damian Garde cited doubts about whether it works, the need for monthly infusions, and a $56,000 average annual price that left Medicare and insurers undecided.

Does Scott Gottlieb think the CDC should be replaced?

No. He says the CDC can and must be fixed, with an operational, national-security mindset, rather than creating a new agency.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Biogen's Aduhelm was approved in June 2021, and by September 11, 2021 about 100 people had received it commercially outside clinical trials.

“Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial.”

0:08:13 · Host · Aduhelm launch · 2021

Biogen priced Aduhelm at an average of $56,000 a year, which Damian Garde said added to skepticism about the drug.

“the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy”

0:09:12 · Host · Aduhelm price · 2021

Aduhelm is an infused therapy given once a month, and Damian Garde said the infrastructure to deliver it was not necessarily in place.

“it's an infused therapy and it's infused once a month is not necessarily in place for people to even get on it”

0:08:44 · Host · Aduhelm logistics · 2021

The FDA authorized Pfizer's Covid booster for people six months past their primary series who are 65 or older or at high risk of severe Covid.

“The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID”

0:04:54 · Meg Terrell · Booster authorization · 2021

Acting FDA Commissioner Janet Woodcock said the high-exposure group for Pfizer boosters includes teachers, daycare workers, grocery workers, and people in prisons and homeless shelters.

“Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.”

0:04:54 · Meg Terrell · Booster eligibility · 2021

Meg Terrell described the booster approval path as FDA advisers, then the FDA, then the CDC's advisory committee, then CDC director sign-off.

“the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it”

0:04:33 · Meg Terrell · Approval process · 2021

Johnson & Johnson released a long press release combining data from several studies, including a second shot given two months later.

“Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later.”

0:05:45 · Meg Terrell · J&J data · 2021

A study of remdesivir in non-hospitalized patients, given as three days of IV treatment, suggested it could keep people out of the hospital, as monoclonal antibodies can.

“You have to get three days of IV treatment. It suggested that can keep you out of the hospital as potentially as well as monoclonal antibodies.”

0:06:14 · Meg Terrell · Remdesivir · 2021

Adam Feuerstein said Merck, Pfizer and another company were developing oral Covid antivirals, and that remdesivir's effect gave reason for optimism.

“oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development”

0:06:44 · Host · Oral antivirals · 2021

The Biden administration wanted boosters for everyone, but the FDA's advisory committee VRPAC said the evidence did not support that.

“the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that.”

0:14:45 · Helen Branswell · Booster debate · 2021

The booster emergency use authorization covered only Pfizer's vaccine, which just under half of vaccinated Americans had received.

“this EUA only covers the Pfizer vaccine. And just under half of the American population that's been vaccinated got the Pfizer vaccine.”

0:16:07 · Helen Branswell · Booster coverage · 2021

Helen Branswell said Covid vaccine priority groups ran on an honor system, with no requirement to prove a health condition.

“there was never any requirement that you prove that you were a diabetic or that you had hypertension”

0:17:25 · Helen Branswell · Vaccine eligibility · 2021

STAT polling found that vaccinated Trump voters were much less likely than vaccinated Biden voters to plan to get a booster.

“A lot fewer vaccinated Trump voters plan to get a booster than vaccinated Biden voters.”

0:18:34 · Meg Terrell · Booster polling · 2021

Helen Branswell said India was expected to supply much of the developing world's vaccine but was swamped by the Delta variant, which disrupted exports.

“India was going to be the producer for much of the developing world. And then India got swamped by the Delta virus”

0:22:58 · Helen Branswell · Vaccine supply · 2021

Former CDC director Tom Frieden criticized Moderna and Pfizer for not sharing expertise and patents to expand vaccine manufacturing abroad.

“he also is really taking aim at the companies, Moderna and Pfizer in particular, for not sharing their expertise and their patents”

0:22:01 · Meg Terrell · Vaccine equity · 2021

Scott Gottlieb sits on the boards of Pfizer and Illumina, is a senior fellow at the American Enterprise Institute, and is a CNBC contributor.

“which also includes board member of Pfizer and Illumina, senior fellow at the American Enterprise Institute and CNBC contributor.”

0:25:35 · Host · Gottlieb roles · 2021

Scott Gottlieb said U.S. pandemic tabletop exercises, including Crimson Contagion just before Covid, were built around an influenza pandemic.

“all of the tabletop exercises that we had done, and I had been a part of some of those, prepped for a potential pandemic with an influenza, including crimson contagion, which happened just before COVID ended up striking.”

0:26:38 · Host · Pandemic preparedness · 2019

Scott Gottlieb said the U.S. stockpile held respirators that did not work and out-of-date masks.

“Respirators that we had stockpiled didn't work. The masks were out of date.”

0:27:08 · Host · Strategic stockpile · 2020

Scott Gottlieb said diagnostic testing was not a major part of pandemic exercises like Crimson Contagion, because flu planning relied on existing doctor's-office flu tests.

“if you look back at the pandemic tabletop exercises like crimson contagion, diagnostic testing wasn't a big part of those exercises.”

0:27:08 · Host · Testing gap · 2019

The host summarized Gottlieb's book as saying the CDC botched its first SARS-CoV-2 test and failed to plan for widespread testing.

“they botched the development of the first SARS-CoV-2 test. They failed to come up with a plan for widespread testing”

0:28:06 · Host · CDC testing · 2020

Scott Gottlieb argued against creating a new agency, like the Department of Homeland Security created after 9/11, for pandemic planning, preferring to reform the CDC.

“we should be creating a new agency or creating a new Department of Homeland Security that's focused on pandemic planning like we did after 9-11.”

0:29:02 · Host · CDC reform · 2021

Chapters

  1. 0:03:32Adam's first post-Covid bar night

    A light opener shows how daily life still involved vaccine proof and masks in September 2021.

    “I had to keep pulling the mask down to to drink, obviously.”
  2. 0:04:54Who can get a Pfizer booster

    Meg Terrell explains the multi-step FDA and CDC process and which groups the FDA authorized.

    “authorized Pfizer's booster for people six months out from their primary vaccination”
  3. 0:08:13Aduhelm's stalled launch

    Biogen's Alzheimer's drug had reached very few patients, defying Wall Street expectations.

    “about 100 people have received the drug on a commercial basis”
  4. 0:11:24Helen Branswell on the winter outlook

    Models suggest Delta could ebb after Thanksgiving, but a new variant remains the major risk.

    “models point to the delta wave sort of subsiding in this country”
  5. 0:14:45A messy booster rollout

    Broad eligibility categories and a Pfizer-only authorization leave many people finding their own route.

    “a lot of people who want boosters are going to find a way”
  6. 0:21:14Global vaccine inequity

    Cold-chain demands, thin supply and COVAX shortfalls mean the world is far from controlling the virus.

    “we're nowhere near bringing this virus under control across the world”
  7. 0:26:38Gottlieb: preparing for the wrong pathogen

    Flu-centered exercises sidelined testing and left the stockpile inadequate.

    “prepped for a potential pandemic with an influenza, including crimson contagion”
  8. 0:29:02Fixing the CDC

    Gottlieb wants a reimagined CDC rather than a new agency.

    “I think it can be fixed and I think it has to be fixed.”
  9. 0:29:24Rebuilding public trust

    Gottlieb says arbitrary-seeming guidance cost health agencies credibility that must be regained.

    “large portion of the population that has lost confidence in public health”

Transcript

0:00:15
Meg Terrell

Welcome to this week's episode of The Readout Loud, a weekly biotech podcast from STAT. I'm Meg Terrell.

0:00:20
Host

I'm Adam Feuerstein. And I'm Damian Garde.

0:00:22
Meg Terrell

It's Thursday, September 23rd. And here's what we're going to talk about this week.

0:00:26
Host

We gave Adam a break from COVID-19 talk last week, so naturally we have to double up this week. And for good reason. Our colleague Helen Branswell has an incredible story out this week about what this winter may have in store. She joins us to discuss it. I appreciate that, Damien. Next up, you've heard his advice for grilling. But did you know that former FDA Commissioner Dr. Scott Gottlieb has also some thoughts on the pandemic? His new book was released Tuesday, and we go in depth with him on what went wrong, beyond the obvious, and how to prevent this from happening again.

0:00:54
Meg Terrell

We'll start with a look at the week in biotech.

0:00:56
Host

But first, a word from our sponsor.

0:01:07
Meg Terrell

Hi, everyone. My name is Maria. My name is Danielle, and Maria and I are the new hosts of Genentech's award-winning podcast, Two Scientists Walk Into a Bar. It's a show for scientists, science geeks, and the people who love them. Aww. So Maria, true story, is from the UK. She's into clinical data, transcription factors, and long runs on the beach. That's right! And Danielle is from Texas. She loves translational medicine, woodworking, and getting up close and personal with cancer cells.

0:01:39

And when we're not botching each other's accents, you can usually find us chatting up other scientists about all kinds of cutting-edge research. So grab a drink and check us out wherever you get your favorite podcasts or find us at gene.com slash podcast. That's G-E -N-E dot com slash podcast. So Adam, let's start by talking about what you did last night. It would normally not be something so exciting, but now it is.

0:02:09
Host

I know. I had fun. Yeah, I discovered these places called bars. It's a bar and you go and there's drinks and then there's a band who's playing live music.

0:02:19
Meg Terrell

Those all sound like terrifying things.

0:02:21
Host

It was a great time. I actually went out last night to see a friend's band called Graveyard of the Atlantic to give them a little bit of a plug. They're a local Boston band. And they actually have a biotech connection because their lead guitarist, Dave DeBaney, is married to Minisha Pai, who does IR at Vertex Pharmaceuticals. So shout out to those guys. And we had a great time last night. It was my first bar experience post-COVID, or not post-COVID, but since COVID.

0:02:53

During COVID, since COVID.

0:02:54
Meg Terrell

So what were the vaccine requirements? Who was wearing masks? How did you drink a drink through a mask?

0:02:59
Host

Yeah, that was kind of an interesting thing. So when you got, and this is like a divy bar, but when you got to the bar, the woman, the very nice woman who was working the door, took my $5 cover charge, also asked me for proof of vaccination. So I showed her a photo of my vaccine card. And, you know, she didn't card me, thank God, because I'm, you know, 500 years old. But yeah, then then you're in and you have to wear masks.

0:03:24

So you wear masks in the bar.

0:03:26
Meg Terrell

So, like, did you drink anything? Like, what do you put a straw through the side of your N95?

0:03:32
Host

Yeah, that was that was kind of the weird thing because I kept I did drink. I had a couple of beers and yeah, I had to keep pulling the mask down to to drink, obviously. But all in all, it was really fun. And it's something that I look forward to doing more of as we get rid of COVID, hopefully. So speaking of being rid of COVID or ideally being rid of COVID, the big news this week, I guess on that front, was this ongoing situation with booster doses and who ought to get them and when they might be available and which governmental authority gets to decide that.

0:04:07

So Meg, where are we as of the moment of this recording?

0:04:10
Meg Terrell

Well, this is Thursday morning. So we are halfway through CDC's advisory committee's two-day meeting on this very topic. And as my husband put it last night, as I was like fielding phone calls or trying to make dinner, just working like a long day covering this entire thing. And the FDA was like rumored to be coming out with its decision. He was like, there are so many steps in this process and all of them are breaking news.

0:04:33

I was like, you just basically described the last year and a half of my life. But he's right. I mean, it's kind of absurd. He's like, didn't the FDA already decide on this on Friday? And I was like, no, that was just its advisory group. And then the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it. And then we get to use the booster shots. So that's essentially where we are now.

0:04:54

The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID and people who have high risk of exposure through their jobs and thus are at higher risk of severe outcomes of COVID. And Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.

0:05:19

So the FDA kind of saying who they think this should be given to, that's the purview of the CDC's advisory committee. So we'll hear their recommendations Thursday afternoon and a vote as well. And then this basically gets, you know, available ostensibly only to people who got Pfizer the first time around. But as we talk about with Helen Branswell later in the episode, it may not be that cut and dry. There was also a ton of other COVID news this week.

0:05:45

Monday morning, we woke up to Pfizer's results for kids ages 5 to 11. And so we're now we're talking about a vaccine for kids by Halloween. Tuesday, we woke up to Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later. They talked about their second shot six months later. But don't worry, guys, the first dose still provides long lasting protection was essentially the gist of that.

0:06:14

Whether we start to hear more about J &J getting used around the world as a single shot vaccine is an open question and probably a very important one. And then we got some news on remdesivir being used on people who are not yet hospitalized. You have to get three days of IV treatment. It suggested that can keep you out of the hospital as potentially as well as monoclonal antibodies. But it was kind of a funny study.

0:06:37

They stopped enrolling early in April. And who's going to get three days of IV treatment? You know.

0:06:44
Host

Yeah. The remdesivir news, I mean, to your point, that's not a very practical thing for someone who is not hospitalized, who's recently diagnosed. But to the extent there's a silver lining, like we already know that the monoclonal antibodies, as you mentioned, do a similar job and are more convenient. But remdesivir being effective as an antiviral could be a good sign for the oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development.

0:07:13

They don't have the same mechanism per se, but just the notion that remdesivir could have an effect in that stage, it could be, you know, reason for optimism about these infinitely more convenient oral treatments that are coming through the pipeline. And shifting gears, Damien, you and I were busy writing a story about, or we're taking a closer look at a certain Alzheimer's drug. That's right. So, yeah, Aduhelm, the star of this podcast, or I guess co-star to COVID-19, that's probably too glib.

0:07:42

But anyway.

0:07:43
Meg Terrell

I thought I was the star of this podcast.

0:07:46
Host

So, yeah. So, you know, we learned from Biogen a couple weeks ago that the commercial launch of Aduhelm, their infinitely discussed treatment for Alzheimer's disease, was going more slowly than the company had anticipated and thus than really everyone else had, or at least Wall Street had. What they didn't mention in that disclosure was just how many patients had been treated with the drug. And you and I learned that. 100 patients. Right. Right. Which is a small number.

0:08:13

I mean, to put it in context, you know, Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial. And based on basically Wall Street's estimates of how much money Biogen would make on Aduhelm in 2021, basically they thought thousands of patients would be getting the drug by now. The fact that it's only about 100 is really cause for a lot of pondering and a lot of revisiting expectations.

0:08:44

And, you know, Biogen came clean, I think, a little bit about what the challenges are. And they're basically, one, a lot of people, physicians, scientists, and even some patients, are really skeptical as to whether this drug works for the reasons that we've discussed for months and months and months and months. But then furthermore, the infrastructure to it's an infused therapy and it's infused once a month is not necessarily in place for people to even get on it, even if they are prescribed the drug.

0:09:12

And then three, the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy, has led to hospital groups, insurers, and largely Medicare really in a tough spot in deciding whether to pay for this. And so, you know, Medicare is deliberating. A lot of groups are deferring to them. And basically Biogen is kind of caught in this position where they got what they wanted in the form of this FDA approval.

0:09:44

But a confluence of factors, some of which are under their control and some of which are not, have made it to where this drug is just not really ending up in patients.

0:09:51
Meg Terrell

As your next scoop on Aduhelm, I would like you guys to focus in on how they reached the $56 ,000 price and if it was a push from the board or if it was some other.

0:10:02
Host

All right, we'll work on that.

0:10:04
Meg Terrell

Thanks, guys. Winter is coming.

0:10:18
Host

Again. That is the lead of a new story from our colleague Helen Branswell, which continues, a year ago, experts warned that the United States faced a grim winter if Americans didn't mask up and social distance to slow transmission of the SARS-CoV-2 virus before indoor weather, aka winter, settled in for its long stay. We all know how well that warning was heated. In January, cases topped 300 ,000 a day and COVID ended the lives of about 95 ,000 Americans before the month was out.

0:10:46

And joining us to discuss the fact that winter is coming is Helen Branswell. Helen,

0:10:51
Meg Terrell

thanks for joining us again. Hi, good to be with you. So Helen, I just absolutely love this story that you wrote this week, because I feel like experts so infrequently are willing to actually talk about what could happen. And you managed to get a lot of really fantastic ones to talk with you about that for this upcoming winter. And of course, you know, the most predominant feeling is uncertainty. But you also quoted some modelers who say things could be looking up from here.

0:11:20

Can you tell us about that? Let's start with a little hope.

0:11:24
Helen Branswell

Sure. So I was, you know, quite uncertain about what to think would be coming this winter myself. So I did reach out to a bunch of people. And one of the people I spoke to was Cécile Vibault, who is an epidemiologist and modeler who works at the Fogarty International Center at the National Institutes of Health. she and a group there are monitoring nine modeling efforts on an ongoing basis and what she said is that the models point to the delta wave sort of subsiding in this country in late November sort of just after Thanksgiving and getting to the point where transmission could be quite low sort of down into the 10 to 15 ,000 cases a day range.

0:12:16

And she said, you know, once it gets down there, it could stay there for a while with the big caveat of, you know, as long as there is no new variant that is able to either escape immunity or become more transmissible still than the Delta

0:12:34
Host

variant. And Helen, obviously Thanksgiving and Christmas are big travel periods for Americans. Does her model factor in the fact that people will be traveling during that time period?

0:12:45
Helen Branswell

Yeah, absolutely. I mean, last year, you know, we really saw the effect of people getting together for Thanksgiving and Christmas in the disease levels that happened after that period. Yes, the models do factor that in. They do look fairly promising as long as there are new variants coming at us in the near term.

0:13:07
Host

So, you know, happening really as we speak is the debate, which seems somewhat settled over just when and for whom booster shots of COVID-19 vaccines will be available in the United States. How does that factor into how epidemiologists and others are looking at this winter, knowing that, you know, some millions of people will be able to get third doses of vaccine?

0:13:33
Helen Branswell

I think this modeling work that we've been talking about, I'm not sure that it factors in third doses. I think it's looking at sort of the amount of immunity there is in the population, both from existing doses that have been administered and the amount of infection that has occurred in the country. But obviously, if people start to get third doses, immunity rates will go up, and that would contribute to lessening spread of the virus.

0:14:03
Meg Terrell

So let's talk about the news this week about the boosters. Helen, I was following your live tweeting of the CDC's Advisory Committee on Immunization Practices meeting on Wednesday, and we're recording this Thursday morning. So we're expecting to get their vote this afternoon by the time a lot of people are listening to this. But on Wednesday night, the FDA authorized Pfizer's booster. And on Twitter, before that happened, you noted, it seems pretty clear that the rollout of a booster shot program is going to be messy as hell.

0:14:35

I think a lot of people agree with you. What's your take on essentially where we are, where this authorization came down and what this is going to look like?

0:14:45
Helen Branswell

So, you know, what FDA said in the final analysis was pretty interesting. Um, the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that. But FDA hasn't actually, you know, outright gone against Virpac, but at the same time, they have added so many groups to this EUA that a lot of people who want boosters are going to find a way to get a booster as a consequence of this EUA.

0:15:25

What they've said is that people who are 65 and older qualify, as do people who are at high risk from COVID, either because of exposure to the disease, which covers health care workers, teachers, daycare workers, people who work in grocery stores. I mean, it's a long list of people who can fit in under the exposure category. And then also people who are at high risk because of health conditions. And again, that's another long list of people, people who are obese, people who have diabetes.

0:16:07

there's a long list of people who could now go to their pharmacy and say, I need to be boosted because I fit into the parameters of this EUA. Where it's going to get messy is that this EUA only covers the Pfizer vaccine. And just under half of the American population that's been vaccinated got the Pfizer vaccine. So there's nothing here for people who got Moderna or people who got Johnson & Johnson. But it's, you know, widely known that some of those people have been seeking boosters anyway and may decide that they won't wait for the FDA to authorize boosters of the Moderna vaccine or the J &J vaccine.

0:16:54

and they may just go get themselves a, you know, a Pfizer booster, sort of going for a mix and match approach to their vaccine regimen.

0:17:03
Host

Is there anything stopping people who maybe don't fit those categories from getting a booster shot? Like I'm thinking about myself, like I'm probably not in any of those categories, although I have put on quite a bit of COVID weight. But like, if I want to go to CVS and get a booster shot, can I go get one?

0:17:25
Helen Branswell

I don't know what would stop you, Adam. I mean, it's always been an honor system. You know, for instance, during the initial rollout, when they, the only way anybody could stop anybody at that point was based on age. Once you get into, you know, categories where people who had certain health conditions could step forward, you know, there was never any requirement that you prove that you were a diabetic or that you had hypertension or that you had any number of the conditions that were listed as putting you in a priority group.

0:18:05

So, you know, I doubt very much if a pharmacist is going to ask you, you know, how do you qualify? If you book the appointment, I think they're going

0:18:14
Host

to give you the vaccine. And just like a related question, is there any researchers, anyone looked in kind of how willing Americans are to get a booster shot. I mean, obviously, getting vaccinated the first time has been very polarizing in this country. Has anyone done looked into that and said, like, how willing will people be to get a third shot? I can answer that question. So we've

0:18:34
Meg Terrell

done some polling on it. And it sounds like people who already were vaccinated, about three quarters of those folks say they plan to get a booster shot. But then if you look at it by who you voted for in 2020, because everything is looked at through a political lens. And unfortunately, this provides illuminating information. A lot fewer vaccinated Trump voters plan to get a booster than vaccinated Biden voters. And even President Trump, who himself is vaccinated, he expressed ambivalence about getting a booster.

0:19:04

And I don't know how much that influences people. But it seems like even folks who are like really on board with getting the vaccine the first time around, maybe sort of changing their minds about it or not feeling so eager to get a booster shot. But But for the most part, it does sound like most people who got vaccinated will get a booster.

0:19:20
Helen Branswell

Yeah, that doesn't surprise me. I would say, though, you know, that if if the models are right and if we start to see the delta wave coming under control in the country, that probably will also depress uptake of boosters. You know, people are motivated to get vaccinated when they're afraid of what's before them.

0:19:38
Host

So zooming out from the United States, where we're all debating whether to get a third dose, obviously, much of the world is desperate for access to even a first one. And there was something of a hopeful note in your story. You spoke to Barney Graham, formerly of the NIH, who was hoping that, you know, between Delta and some of the other epidemiological trends, that conceivably the virus is trapped right now. And so if we can immunize as many people as possible around the world, we could be looking at, you know, kind of cresting the wave of this virus.

0:20:11

And so I guess my question is, you know, where are we on the global distribution of vaccine process versus, you know, like how many months might we be away from from reaching something like herd immunity on a global scale?

0:20:25
Helen Branswell

Oh, that's a long way off. I'm sorry to be a downer at this point, but many, many countries have still vaccinated a very small proportion of their people. There are still far too few vaccines available to low and middle income countries. uh the you know part of the problem is the vaccine that you know in our part of the world has been produced to the largest degree is the Pfizer vaccine and it's the hardest one to deliver um so you know in places where um cold chain is is not necessarily um robust you know this is a very hard vaccine to get out into the last mile.

0:21:14

You probably will remember that COVAX, which is the enterprise that the World Health Association, CEPI and Gavi, have partnered on to try to procure vaccine doses for countries that can't buy them for themselves. They recently downgraded their estimate of how much vaccine they're going to be able to provide this year. And, you know, that may not be the end of that story. I mean, I don't know that I actually think herd immunity can exist on a global scale, but, you know, we're nowhere near bringing this virus under control across the world.

0:22:01
Meg Terrell

Alan, I'm curious to know, you know, we've seen Dr. Tom Frieden, the former CDC director, really come out pretty strongly about this issue in the last week or two, taking aim both at the Biden administration for not doing enough, not just in terms of donating vaccines, but also equipping nations to whom are donating them with the cold chain requirements and helping pay vaccinators or things like that. But he also is really taking aim at the companies, Moderna and Pfizer in particular, for not sharing their expertise and their patents and helping set up manufacturing in these countries.

0:22:37

I'm just wondering, you know, we had the Pfizer CEO, Albert Bourla on CNBC on Wednesday and asked him about that because they say it's a mid to long term goal of setting up MRNA manufacturing in these other places. How do you just reconcile what you're hearing from both sides about that? How do you think about it?

0:22:58
Helen Branswell

Well, I don't think there's a quick or easy fix. I mean, you know, what has become very clear in this pandemic is that people will take care of their own. And so the world definitely needs a lot more capacity and a lot more capacity spread out. You know, India was going to be the producer for much of the developing world. And then India got swamped by the Delta virus and India has an exported vaccine. You know, that was actually a foreseeable problem.

0:23:31

You know, there were people who were talking about the need to produce in small population countries because countries would close borders, you know, if things got bad. going forward, you know, I think there's going to be a huge push to disseminate capacity to produce around the world. I suspect, you know, at least some of that is going to be based on the mRNA platform, but it may not all be. And frankly, you know, what would be really useful at this point is if some of the other vaccines that are much easier to administer could be pushed out in greater degrees.

0:24:13

You know, J &J, still not a lot of product there, but that vaccine could be very useful internationally. The AZ vaccine, you know, AstraZeneca, that vaccine will be really useful in an international setting. If Novavax can manage to consistently produce vaccine to high levels. Everybody has huge hopes for that vaccine. Having some other options available would be really, really helpful. And hopefully that will start to happen soon.

0:24:52
Host

Helen, thanks for joining us again.

0:24:53
Helen Branswell

Thanks for having me, guys.

0:25:06
Host

The virus didn't arrive with a group of visitors from China where it originated, or from Italy, where it established its next major foothold. Instead, it likely rode along the breadth of probably hundreds of different travelers from a variety of locations, each ferrying the infection and evading the poorest controls that the federal government had put in place at U.S. airports. At the time, nobody knew what was happening. No one knew how much virus was being carried by people who showed no outward symptoms of the disease.

0:25:35

These were people who might never manifest any signs of illness, but were still contagious. Without the ability to test people for the virus, we had no way of detecting its spread. We certainly had no way of stopping it. Former FDA Commissioner Dr. Scott Gottlieb can now add published author to his long list of titles, which also includes board member of Pfizer and Illumina, senior fellow at the American Enterprise Institute and CNBC contributor. His book about the pandemic, Uncontrolled Spread, Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic was released Tuesday.

0:26:06

You just heard him reading an excerpt from it. And he joins us now to talk about it. Dr. Gottlieb, welcome back to the Readout Loud. Thanks for having me.

0:26:12
Meg Terrell

So Scott, one of the themes in your book is how we thought we were prepared for something like this. But you point out that all those plans turned out to be what you call a technocratic illusion, which is just such an evocative phrase. Our stockpile was drastically insufficient. And at the core of the issue, you write that we prepared for the wrong pathogen. So why was the U.S. so convinced that the next pandemic would be a flu?

0:26:35

And why were we so unable to pivot when it turned

0:26:38
Host

out to be something different? Well, all of the tabletop exercises that we had done, and I had been a part of some of those, prepped for a potential pandemic with an influenza, including crimson contagion, which happened just before COVID ended up striking. And, you know, if you're looking at pandemic preparedness through the lens of a potential pathogen like influenza, the types of things you worry about and focus on are different. First of all, the preparations that we had made for a flu were inadequate.

0:27:08

And the stockpile is just one metaphor for that inadequacy, where we had things in the stockpile that simply didn't work. Respirators that we had stockpiled didn't work. The masks were out of date. Certain contingencies that become very important in preparing for a coronavirus aren't as important when it comes to flu. So for example, diagnostic testing isn't going to be an essential component to actually responding to a pandemic with flu. And if you look back at the pandemic tabletop exercises like crimson contagion, diagnostic testing wasn't a big part of those exercises.

0:27:37

There was no difficulty getting access to screening because with an influenza, the incubation period is very short and people are typically contagious. after they manifest symptoms. So getting people diagnosed while they're asymptomatic as a way to control the spread of the pathogen isn't as critical. And also the nation's installed base of testing equipment that's in every doctor's office that can test for influenza A or influenza B would be sufficient. You wouldn't have to do PCR testing and get the exact viral sequence of the strain that was infecting them.

0:28:06

So you had an installed base of testing. So by looking at pandemic preparedness through the lens of influenza, things that became very important for a coronavirus were relegated when it came to trying to prep for a pandemic with influenza. So, Scott, in the book, you know, you're very critical of the Centers for Disease Control and Prevention. You point out that in the early days of the pandemic, the agency, you know, they botched the development of the first SARS-CoV-2 test.

0:28:32

They failed to come up with a plan for widespread testing and actually impeded rather than assisted the development of tests by outside commercial labs. And you also criticize the CDC for some of its public health guidelines, like establishing the six foot social distancing requirement, you know, without evidence that that would help. So I guess the question here is, you know, can the CDC be fixed and should it be fixed? Meaning, should we be relying on the CDC in future pandemics or should the responsibilities for surveillance and response go somewhere else?

0:29:02

I think it can be fixed and I think it has to be fixed. I don't think that when we engage in pandemic planning going forward and we come together and have a commission and try to reach a bipartisan consensus on what the new framework is going to look like, that we should be creating a new agency or creating a new Department of Homeland Security that's focused on pandemic planning like we did after 9-11. And I think we need to vest these kinds of capabilities within CDC.

0:29:24

But it's a reimagined CDC. It's a CDC that has an operational focus, has a national security mindset that isn't so retrospective, that's comfortable surfacing real time information to inform active policy decision making, even if it isn't certain. An even more fundamental challenge that we're going to face, in my view, at least, is that there is now a large portion of the population that has lost confidence in public health decision making in the setting of a crisis that has lost confidence in the guidance that was issued, that felt that the recommendations were arbitrary, that they were inconsistent, that they weren't articulated in a way that people could find practical value from the issues of should I wear a mask?

0:30:06

Shouldn't I wear a mask? Things seemed arbitrary. They didn't seem science based in many cases because they were arbitrary and they weren't grounded on good science. And the agency wasn't transparent about how speculative some of the recommendations were at the time that they were being made. And so people have now lost confidence in public health officials to issue guidance in a setting of a crisis. And this is this breaks down along ideological lines for sure. I mean, there is a right left divide on this, but it is much broader than that.

0:30:31

I think it transcends just pure politics. And so we're going to need to earn back the public's trust and convince them that public health agencies should be empowered in a setting of a public health crisis before we even have the discussion about how then to empower public health agencies going forward in the setting of a public health crisis. And it's going to require some self-awareness on the part of public health officials that there were certain aspects of what we did that also failed.

0:30:57

So sort of on that point, you know, your book does focus mostly on the agency level and you deliberately avoid framing too many of the failures in political terms. But so many of the decisions in question, whether federal, state or local, are made by elected officials. And so considering that voting is pretty much the only thing most readers of your book can do to influence the nation's future pandemic preparedness, what should we be saying to our leaders and our political candidates?

0:31:22

Like, what would a pandemic smart platform look like? Yeah, I think that voters should care about public health and voters should care about candidates being willing to invest in strong public health measures, strong public health infrastructure. And that transcends just pandemic preparedness. I mean, this pandemic showed how excessively vulnerable our society is because of systemic challenges that we face with getting adequate health care to communities in society that were made excessively vulnerable to COVID precisely because they lacked access to care.

0:32:01

They faced bias in how care was delivered. They worked in jobs where they didn't have the social capital at work to demand conditions that would keep them safe. Something as simple as a mask on the job, a high quality mask, if you were working in a confined space that was conducive to spread. So I think voters should care about politicians being willing to take strong positions on trying to reinvigorate the nation's public health. That's why I say, you know, we have to have this discussion about how to properly empower resource the CDC, how to change its orientation, how to give it more of a national security mindset.

0:32:36

But all of that is predicated on a belief that you think public health institutions should be strong. And there's a lot of people who are very skeptical of that notion. And it's a lot of conservatives. It's a lot of, you know, my my my fellow conservatives, but it's broader than that. And that really worries me. Building back that consensus, I think, is going to be difficult.

0:32:55
Meg Terrell

Well, I wonder what do you see as your role in helping accomplish that? You have this unique position now. You were in government. You're no longer in government. You sit on many different seats of power and access. Do you ever think about going back in? Would you be a sort of pandemic preparedness czar? Are you the person to coordinate this on the government level or are you more effective from this sort of more private sector role you've now taken on?

0:33:24
Host

I haven't really thought about how I could be effective or where I could be most effective from in this debate. I mean, I look at this through the lens of where I am right now, and I think I could be effective in trying to just articulate why it's important, why it's important that we have strong public health institutions that are able to execute this kind of a mission. It's not just about building a better CDC, but it's about looking at why certain communities were made excessively vulnerable and how do we rectify that.

0:33:55

What's your access like today with the Biden administration? Obviously, you know, in the book, you talked about having like a lot of access being at the White House under the Trump administration. You know, what is it like under a Democratic president today? Are they are people listening to you? I have dialogue with with members of the Biden administration. I've had pre-existing relationships with a number of people who are in in roles right now where they have involvement in the response to COVID.

0:34:20

And I maintain those relationships and maintain that dialogue. I'm going to preserve the, you know, the discretion of the people who reach out to me and talk to me from time to time or on a more routine basis. But I feel that if I have a strong opinion on something that the Biden administration, people in the Biden administration who are in positions of authority and able to, you know, execute on aspects of this response are willing to take my call.

0:34:46

And I'm very grateful for that. So last question, you know, in the book, or rather you dedicate the book to your three daughters. And, you know, as we mentioned before, you were on CNBC most days, sometimes starting at 6 a.m. Throughout that whole pandemic, you're on several boards. You have, I think, at least two day jobs at AEI and NEA. And then plus you wrote a book. So I guess this is the sort of like talk show question.

0:35:08

But how did you do it? All my free time was spent writing this book. And that's why I dedicated the book to my family, because I really was absent over the last year. I mean, I spent every moment that I had that I wasn't engaged in something where I had to, you know, work on behalf of NEA. or something related to AI or Pfizer or some of the other business engagements that I have writing this book.

0:35:36

So it consumed all my free time.

0:35:37
Meg Terrell

Well, I bet they're excited that you'll be done with book publicity soon and they'll get to hang out with daddy.

0:35:42
Host

Thanks, Meg. That does it for another episode of The Readout Loud. Thank you to Teresa Gaffney for producing this week's episode.

0:35:59
Meg Terrell

Our senior producers are Hyacinth Empanado and Alyssa Ambrose.

0:36:02
Host

Our executive producer is Rick Burke. And our theme music is by Brian Joel.

0:36:06
Meg Terrell

And we'd love to hear from you. Tell us what you like about this week's episode, what you didn't like, and how you drink through a mask. You can do all that by sending us an email at readoutloud at statnews.com.

0:36:16
Host

And if you like what we do, leave a review or a rating on Apple Podcasts or whichever platform you use to get your podcasts. See you next week. Thank you.